Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

New Crypto Pepeto Passes $8.25M While Dogecoin Price Prediction Heats Up and Elon Musk Confirms X Money Goes Live in April

View original at globenewswire.com
New Crypto Pepeto Passes $8.25M While Dogecoin Price Prediction Heats Up and Elon Musk Confirms X Money Goes Live in April Dubai, UAE, March 21, 2026 (GLOBE NEWSWIRE) -- Pepeto just cleared $8.25 million in presale and every signal around this new crypto is lining up in a way the market has witnessed only twice, once w…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The most bullish dogecoin price prediction puts this cycle between $0.30 and $0.47 with $1.00 as the long term ceiling

    60% confidence

  • Pepeto is the first cryptocurrency to combine meme appeal with DeFi functionality

    60% confidence

  • X Money will open to the public in April with peer-to-peer transfers, a Visa debit card, 6% APY, and availability across 40 states

    60% confidence

  • Smart Cashtags for crypto trading are on the way, with future Dogecoin support hinted

    60% confidence

  • X Money was already running in closed beta, with a limited public launch coming before the worldwide rollout

    60% confidence

  • Pepeto could be the next name Elon Musk mentions on X

    60% confidence

  • Whale addresses have a history of knowing things before the market does and may have already received confirmation about Elon Musk connections

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com